NCT07408349 Guided Imagery of the Gynecological Cancer
| NCT ID | NCT07408349 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Baskent University |
| Condition | Gynecologic Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 46 participants |
| Start Date | 2026-01-19 |
| Primary Completion | 2026-06-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 46 participants in total. It began in 2026-01-19 with a primary completion date of 2026-06-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this randomized controlled trial is to evaluate the effectiveness of a guided imagery intervention in women receiving chemotherapy for gynecological cancers at Başkent University Ankara Hospital Outpatient Chemotherapy Unit. The main questions it aims to answer are: Does guided imagery improve psychological or physical outcomes during chemotherapy? How do outcomes differ between the intervention (guided imagery) and control (standard information) groups? Researchers will compare both groups to assess the effect of guided imagery across three repeated measurements. Participants will: * Be randomly assigned (1:1) to intervention or control groups via an online randomization tool. * Complete outcome assessments at three time points. * Be part of a sample of 158 women (minimum 76 per group), based on power analysis for repeated measures ANOVA (effect size f = 0.25, 95% power, 95% confidence). The study will follow the CONSORT-Outcomes 2022 guideline and be registered at ClinicalTrials.gov.
Eligibility Criteria
Inclusion Criteria: * Having a diagnosis of another type of cancer * An ECOG (Eastern Cooperative Oncology Group) performance score of ≥3 (PS 3: Confined to bed for more than half of the day, limited self-care; PS 4: Completely bedridden, unable to perform self-care) Exclusion Criteria: * Choosing to withdraw from the study * Refusing to practice guided imagery before chemotherapy treatment
Contact & Investigator
Hatice Kübra YURDAKUL, Msc
STUDY DIRECTOR
Baskent University
Frequently Asked Questions
Who can join the NCT07408349 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 90 Years, studying Gynecologic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07408349 currently recruiting?
Yes, NCT07408349 is actively recruiting participants. Contact the research team at kubraoz86@hotmail.com for enrollment information.
Where is the NCT07408349 trial being conducted?
This trial is being conducted at Ankara, Turkey (Türkiye), Ankara, Turkey (Türkiye).
Who is sponsoring the NCT07408349 clinical trial?
NCT07408349 is sponsored by Baskent University. The principal investigator is Hatice Kübra YURDAKUL, Msc at Baskent University. The trial plans to enroll 46 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.